Eli Lilly (LLY) Rated Outperform With Strong GLP-1 Prospects

Eli Lilly & Company (NYSE:LLY) ranks among the stocks with low beta that can beat market volatility. Following the European Association for the Study of Diabetes (EASD) meeting, Bernstein SocGen Group affirmed its Outperform rating on Eli Lilly & Company (NYSE:LLY) with a $1,100 price target.

In its analysis, the firm stated that it had “greater confidence in orfo as the leading oral GLP-1” drug. Bernstein’s analysis drew from important information that was provided during the conference, conversations with prominent figures on obesity, and Eli Lilly’s sell-side event.

Additionally, Bernstein saw a trend among physicians demonstrating “reduced willingness to accept placebo-controlled trials,” which the firm believes is key for upcoming pivotal development initiatives in the GLP-1 domain.

Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.